Chronic oedema/lymphoedema: Under-recognised and under-treated

David H. Keast, Marc Despatis, Jill O. Allen, Alain Brassard

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Even though it is estimated that at least 300 000 people in Canada may be affected by chronic oedema/lymphoedema, recognition of the seriousness of this chronic disease in health care is scarce. Lymphoedema affects up to 70% of breast and prostate cancer patients, substantially increasing their postoperative medical costs. Adding to this problem are the escalating rates of morbid obesity across North America and the fact that 80% of these individuals are thought to suffer with an element of lymphoedema. The costs related to these patient populations and their consumption of health care resources are alarming. Untreated chronic oedema/lymphoedema is progressive and leads to infection, disfigurement, disability and in some cases even death. Thus, prognosis for the patient is far worse and treatment is more costly when the disease is not identified and treated in the earlier stages. Although the number of individuals coping with chronic oedema/lymphoedema continues to increase, the disparity between diagnosis, treatment and funding across Canada endures. The reasons for this include a lack of public awareness of the condition, insufficient education and knowledge among health care providers regarding aetiology and management and limited financial coverage to support appropriate methods and materials.

Original languageEnglish (US)
Pages (from-to)328-333
Number of pages6
JournalInternational Wound Journal
Volume12
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Lymphedema
Edema
Canada
Delivery of Health Care
Costs and Cost Analysis
Morbid Obesity
Health Resources
North America
Health Personnel
Prostatic Neoplasms
Chronic Disease
Breast Neoplasms
Education
Therapeutics
Infection
Population

Keywords

  • Chronic oedema
  • Compression
  • Erysipelas
  • Lymphoedema
  • Venous insufficiency

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Chronic oedema/lymphoedema : Under-recognised and under-treated. / Keast, David H.; Despatis, Marc; Allen, Jill O.; Brassard, Alain.

In: International Wound Journal, Vol. 12, No. 3, 01.01.2015, p. 328-333.

Research output: Contribution to journalArticle

Keast, David H. ; Despatis, Marc ; Allen, Jill O. ; Brassard, Alain. / Chronic oedema/lymphoedema : Under-recognised and under-treated. In: International Wound Journal. 2015 ; Vol. 12, No. 3. pp. 328-333.
@article{e34d6de0c80e4bf08704385cf5ac924e,
title = "Chronic oedema/lymphoedema: Under-recognised and under-treated",
abstract = "Even though it is estimated that at least 300 000 people in Canada may be affected by chronic oedema/lymphoedema, recognition of the seriousness of this chronic disease in health care is scarce. Lymphoedema affects up to 70{\%} of breast and prostate cancer patients, substantially increasing their postoperative medical costs. Adding to this problem are the escalating rates of morbid obesity across North America and the fact that 80{\%} of these individuals are thought to suffer with an element of lymphoedema. The costs related to these patient populations and their consumption of health care resources are alarming. Untreated chronic oedema/lymphoedema is progressive and leads to infection, disfigurement, disability and in some cases even death. Thus, prognosis for the patient is far worse and treatment is more costly when the disease is not identified and treated in the earlier stages. Although the number of individuals coping with chronic oedema/lymphoedema continues to increase, the disparity between diagnosis, treatment and funding across Canada endures. The reasons for this include a lack of public awareness of the condition, insufficient education and knowledge among health care providers regarding aetiology and management and limited financial coverage to support appropriate methods and materials.",
keywords = "Chronic oedema, Compression, Erysipelas, Lymphoedema, Venous insufficiency",
author = "Keast, {David H.} and Marc Despatis and Allen, {Jill O.} and Alain Brassard",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/iwj.12224",
language = "English (US)",
volume = "12",
pages = "328--333",
journal = "International Wound Journal",
issn = "1742-4801",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Chronic oedema/lymphoedema

T2 - Under-recognised and under-treated

AU - Keast, David H.

AU - Despatis, Marc

AU - Allen, Jill O.

AU - Brassard, Alain

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Even though it is estimated that at least 300 000 people in Canada may be affected by chronic oedema/lymphoedema, recognition of the seriousness of this chronic disease in health care is scarce. Lymphoedema affects up to 70% of breast and prostate cancer patients, substantially increasing their postoperative medical costs. Adding to this problem are the escalating rates of morbid obesity across North America and the fact that 80% of these individuals are thought to suffer with an element of lymphoedema. The costs related to these patient populations and their consumption of health care resources are alarming. Untreated chronic oedema/lymphoedema is progressive and leads to infection, disfigurement, disability and in some cases even death. Thus, prognosis for the patient is far worse and treatment is more costly when the disease is not identified and treated in the earlier stages. Although the number of individuals coping with chronic oedema/lymphoedema continues to increase, the disparity between diagnosis, treatment and funding across Canada endures. The reasons for this include a lack of public awareness of the condition, insufficient education and knowledge among health care providers regarding aetiology and management and limited financial coverage to support appropriate methods and materials.

AB - Even though it is estimated that at least 300 000 people in Canada may be affected by chronic oedema/lymphoedema, recognition of the seriousness of this chronic disease in health care is scarce. Lymphoedema affects up to 70% of breast and prostate cancer patients, substantially increasing their postoperative medical costs. Adding to this problem are the escalating rates of morbid obesity across North America and the fact that 80% of these individuals are thought to suffer with an element of lymphoedema. The costs related to these patient populations and their consumption of health care resources are alarming. Untreated chronic oedema/lymphoedema is progressive and leads to infection, disfigurement, disability and in some cases even death. Thus, prognosis for the patient is far worse and treatment is more costly when the disease is not identified and treated in the earlier stages. Although the number of individuals coping with chronic oedema/lymphoedema continues to increase, the disparity between diagnosis, treatment and funding across Canada endures. The reasons for this include a lack of public awareness of the condition, insufficient education and knowledge among health care providers regarding aetiology and management and limited financial coverage to support appropriate methods and materials.

KW - Chronic oedema

KW - Compression

KW - Erysipelas

KW - Lymphoedema

KW - Venous insufficiency

UR - http://www.scopus.com/inward/record.url?scp=84929283894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929283894&partnerID=8YFLogxK

U2 - 10.1111/iwj.12224

DO - 10.1111/iwj.12224

M3 - Article

C2 - 24618210

AN - SCOPUS:84929283894

VL - 12

SP - 328

EP - 333

JO - International Wound Journal

JF - International Wound Journal

SN - 1742-4801

IS - 3

ER -